BACK

Regina Gabitova

Regina Gabitova

Associate

London Office  |  regina.gabitova@torreya.com   |   +44 (0) 207 451 4554

Regina Gabitova, an Associate in Torreya’s London office, oversees transaction support on a variety of European investment banking assignments.

She joined Torreya in 2014.

Regina holds an M.A. (honors) in economics and mathematics from the University of St. Andrews, UK. She is fluent in Russian.

Selected Transactions

Lysogene
Licensing of ex European rights for LYS-SAF302 to
Sarepta Therapeutics
$15 million upfrontwith up to $110m in additional payments plus royalties
October 2018
Shield Therapeutics
Licensing Agreement for Feraccru® in Europe, Australia and New Zealand with
Norgine
£11 million upfront(plus up to £54.5m in milestones and 25-40% royalties)
September 2018
Atopix
Company sale to
Chiesi
> €75 million
November 2016
DBV Technologies
License of
milk allergy product to
Nestle
€100 million
May 2016
Midatech Pharma
Acquisition of
Dara Biosciences
Up to $30 million
December 2015
Midatech Pharma PLC
Sale of Midatech Pharma US Inc. to Kanwa Holdings LP, an affiliate of Barings LLC
None
Up to $19 million
November 2018
Ipsen
Acquisition of
OctreoPharm Sciences
Up to €50 million
May 2015
Probiodrug
Financial advisor
on IPO
Undisclosed
$30 million
October 2014